| Similar Articles |
|---|
 |
Chemistry World
June 19, 2013
Laura Howes |
AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city.   |
Chemistry World
December 10, 2014 |
Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council. |
Chemistry World
March 26, 2014
Phillip Broadwith |
AstraZeneca boosts open innovation efforts Astrazeneca has launched a new web portal, bringing together new and existing open innovation programs. The aim is to make collaboration with academics, other companies, governments and non-government organizations easier. |
Chemistry World
May 7, 2013
Phillip Broadwith |
AstraZeneca site to become biotech hub The first three companies have already moved in, and more will hopefully follow to fill the space left by AZ as it relocates to Cambridge, UK. |
Chemistry World
April 2, 2013
Bibiana Campos Seijo |
More job cuts... The news came in that AstraZeneca is to invest 330 million pounds in a new strategic R&D center and global headquarters in Cambridge, UK. Unfortunately, there is also a negative angle to this story. |
Chemistry World
July 2010 |
Supporting science The Wellcome Trust is one of the largest science funding bodies in the world. Sir Mark Walport, the trust's director, tells Phillip Broadwith how it spends its money |
Chemistry World
March 19, 2013
Simon Hadlington |
Global AstraZeneca restructuring will cost 1600 jobs The company's global research blueprint will now be centered on the creation of three 'strategic R&D centers' for small molecules and biologics, to be based in Cambridge in the UK, Gaithersburg in Maryland, US, and Molndal in Sweden, to be completed by 2016. |
Chemistry World
January 30, 2014
Phillip Broadwith |
AstraZeneca ends R&D in India Pharmaceutical firm AstraZeneca is quitting its R&D site in Bangalore, India. |
Chemistry World
October 29, 2013
Patrick Walter |
GSK forms Brazilian sustainable chemistry venture GlaxoSmithKline has partnered with a Brazilian research organization to create a center to tackle the environmental impact of discovering and making drugs. |
The Motley Fool
November 23, 2004
Brian Gorman |
AstraZeneca Buys Into Cambridge Antibody Cambridge Antibody scored a new alliance, although the deal threatens to make it a house divided. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion. |
The Motley Fool
May 15, 2006
Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
IndustryWeek
January 1, 2004
John S. McClenahen |
Expanding The Discovery Channel Additional R&D labs at AstraZeneca in Waltham, Mass., promise to aid in development of cancer and infectious disease drugs. |
Information Today
March 20, 2014 |
Cambridge University Press Plans New Database Cambridge University Press partnered with East View Information Services to build a fully searchable online platform for selling primary source research collections about regions in Asia. |
Chemistry World
May 28, 2014
Phillip Broadwith |
Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules. |
Information Today
August 5, 2014 |
Wellcome Library and Jisc Will Digitize Historic Medical Books The Wellcome Library, part of the Wellcome Trust, and Jisc partnered with nine institutions, including six universities, for a 2-year digitization project encompassing 19th-century medical books and pamphlets. |
Bio-IT World
March 8, 2005
Kevin Davies |
Birney Wins Franklin Award The young British bioinformatician and Ensembl project leader will be be honored at the Bio IT World Conference and Expo in May. |
Bio-IT World
November 14, 2003
Malorye Branca |
Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines. |
Chemistry World
February 4, 2010
Matt Wilkinson |
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. |
Chemistry World
May 14, 2014
Andy Extance |
Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca. |
Chemistry World
January 28, 2010
Nina Notman |
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. |
Information Today
July 28, 2011 |
Wellcome Library Partners With ProQuest to Digitize Early European Books The collection will be made available through ProQuest's new Early European Books database, a sister project to the Early English Books Online. |
Chemistry World
August 1, 2012
Patrick Walter |
Phenomenal Olympic science legacy (or is that sustainability?) What do you do with a lab set up solely to catch Olympic drug cheats once the games are over? In the case of the London 2012 games, the answer is to turn it into a state of the art analytical lab. |
Chemistry World
May 19, 2014
Phillip Broadwith |
AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'. |
Chemistry World
February 2, 2012
Andrew Turley |
AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term. |
Chemistry World
July 15, 2008
Hepeng Jia |
Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients. |
Bio-IT World
May 7, 2002
Malorye Branca |
In Silico Survivors Facing desperate times, bioinformatics companies revamp, refocus, or perish. |
Chemistry World
March 2, 2015
Phillip Broadwith |
AstraZeneca to spin off anti-infectives research The new company's principal asset will be the novel gyrase inhibitor AZD0914, which is currently in Phase II clinical trials for treating gonorrhea. |
